US FDA to hold workshop on nanomaterial-containing devices
This article was originally published in Clinica
The US Food and Drug Administration plans to hold a public workshop on 23 September to gather information on the manufacturing, characterisation and biocompatibility evaluation of medical devices and diagnostics that contain or use nanomaterials and nanostructures.
You may also be interested in...
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
EU drug industry federation, EFPIA, is concerned that an increase in protectionist trade measures by some countries could result in tit-for-tat policies that could hamper the global response to contain COVID-19.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.